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Nef is a multifunctional virulence factor of primate lentiviruses that facilitates viral replication in the
infected host. All known functions of Nef require that it be myristoylated at its N terminus. This reaction is
catalyzed by N-myristoyltransferases (NMTs), which transfer myristate from myristoyl coenzyme A (myristoyl-
CoA) to the N-terminal glycine of substrate proteins. Two NMT isoforms (NMT-1 and NMT-2) are expressed
in mammalian cells. To provide a better mechanistic understanding of Nef function, we used biochemical and
microsequencing techniques to isolate and identify Nef-associated proteins. Through these studies, NMT-1 was
identified as an abundant Nef-associated protein. The Nef–NMT-1 complex is most likely a transient inter-
mediate of the myristoylation reaction of Nef and is modulated by agents which affect the size of the
myristoyl-CoA pool in the cell. We also examined two other proteins that bear an N-terminal myristoylation
signal, human immunodeficiency virus type 1 Gag and Hck protein tyrosine kinase, and found that Gag bound
preferentially the NMT-2 isoform, while Hck bound mostly to NMT-1. Recognition of different NMT isoforms
by these viral and cellular substrate proteins suggests nonoverlapping roles for these enzymes in vivo and
reveals a potential for the development of inhibitors that target the myristoylation of specific viral substrates
more selectively.
Nef proteins are important virulence factors of primate len-
tiviruses (human immunodeficiency virus type 1 [HIV-1],
HIV-2, and simian immunodeficiency virus [SIV]) (21, 22).
These multifunctional proteins modify the cellular environ-
ment of infected cells to facilitate viral replication and evade
detection by cells of the immune system (9, 27, 41). Nef usurps
at least two distinct mechanisms as it downregulates the cell
surface expression of receptors that are important for normal
immune function. Both HIV-1 and SIV Nef proteins induce
endocytosis of CD4 and CD28 via the AP-2 clathrin adaptor
pathway (1, 4, 15, 24, 33, 44). SIVmac 239 Nef induces T-cell
receptor (TCR):CD3 endocytosis through the AP-2 mecha-
nism as well (3, 45). Interestingly, lentiviral Nef also downregu-
lates cell surface class I major histocompatibility complexes,
through a mechanism that involves PACS-1 and possibly ARF
GTPases (6, 16, 23, 34, 40). Finally, Nef targets signal trans-
duction machinery in T cells and enhances replication and
infectivity of viral particles (8, 18, 20, 25, 27, 39).
These diverse functions are executed through independent
interactions of Nef with a broad array of downstream effectors
in protein sorting and signaling machineries. For example, the
accelerated endocytosis of TCR:CD3 by Nef is mediated by
formation of higher-order protein complexes in which Nef, the
CD3 subunit of TCR:CD3, and the AP-2 clathrin adaptor
bind cooperatively (18, 45). Specific recruitment of other cell
surface receptors to the endocytic machinery is likely mediated
by similar mechanisms. Nef also forms stable complexes with
several elements in the Rac signaling pathway that control
various aspects of cell signaling and the cytoskeleton, including
DOCK2-ELMO1 and possibly Vav guanine nucleotide ex-
change factors, Rac, and p21-activated kinase (PAK2) (2, 10,
20, 31, 36, 37).
All previously described Nef functions require that a func-
tional myristoylation signal be present at the N terminus of Nef
(26, 32, 38, 42, 50). N myristoylation is catalyzed by the enzyme
myristoyl coenzyme A (myristoyl-CoA):protein N-myristoyl-
transferase (NMT), which transfers a myristic acid moiety
(C14:0) from myristoyl-CoA and attaches it via an amide bond
to the N-terminal glycines of both cellular and viral substrate
proteins (5, 7). At least two mammalian NMT isoforms
(NMT-1 and NMT-2) exist and are encoded by separate genes
in both the mouse and human genomes (12, 13).
Molecular mechanisms that mediate a subset of Nef func-
tions such as downregulation of cell surface receptors have
been described in considerable detail, whereas interactions
with other cellular machineries are less clear. To reveal other
events leading to Nef biogenesis and function, we carried out
biochemical and protein microsequencing experiments in-
tended to identify host cell proteins with which Nef associates.
Previously, we reported that the DOCK2-ELMO1-Rac com-
plex is a major target of Nef for signal transduction in T cells
and that HIV-1 Nef activates Rac through binding to this
complex (20). Here, using a similar strategy, we found that Nef
forms a stable complex specifically with N-myristoyltransferase
isoform 1. The association requires an N-terminal region of
Nef containing an intact myristoylation signal, is modulated by
agents that alter the cellular myristoyl-CoA pool, and, there-
fore, represents a transient intermediate of the myristoylation
reaction of Nef. We further demonstrated that two other NMT
substrates, HIV-1 Gag and cellular protein tyrosine kinase
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Hck, also associate with NMT but show different isoform pref-
erences.
MATERIALS AND METHODS
Mammalian expression plasmids and epitope tagging. Dual-epitope-tagged
nef genes were constructed by fusing a sequence encoding the AU-1 epitope (29)
(DTYRYI, A epitope) derived from bovine papillomavirus major capsid protein,
followed by the hemagglutinin (HA) epitope (30) (ANATYPYDVPDYAG, H
epitope) derived from influenza virus hemagglutinin, to the C-terminal amino
acid in HIV-1 NA7 nef (NA7.AH) and in SIVmac 239 nef (239.AH). The
wild-type NA7 and 239 nef allele as well as NA7(G2A), 239(P104A,P107A), and
239(23–74) mutants were described previously (19, 26, 35, 43). In 239(G2ƒ).AH,
the glycine at position 2 in SIVmac 239 Nef was replaced with the AH epitope.
Epitope-tagged nef genes were subcloned into pCG (16) and BABE(puro) (28)
mammalian expression vectors. The AH epitope-tagged green fluorescent pro-
tein (GFP) gene was constructed as described above for nef. Genes encoding
human NMT-1 and NMT-2 were generously provided by B. Cravatt (Scripps
Research Institute) and modified to encode a T7 epitope (MASMTGGQQMG)
at the N terminus of NMT. Genes encoding Nef-GFP fusion protein and H-
tagged HIV-1 NL4-3 Gag and human Hck protein tyrosine kinase were con-
structed by using overlap PCR as previously described (15) and subcloned into
pCG mammalian expression vectors.
Cell lines and retroviral transduction. Jurkat T cells were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glu-
tamine, 10 mM HEPES (pH 7.4), and antibiotics (100 U of penicillin per ml and
100 g of streptomycin per ml) (16). Phoenix-ampho packaging cells (kindly
provided by G. Nolan, Stanford University) and Cos-7 cells (14) were maintained
in Dulbecco modified Eagle medium supplemented as described above. BABE-
(puro) plasmids were transfected into Phoenix-ampho cells by calcium phosphate
coprecipitation method (46). Virus-containing cell culture medium was removed
48 h after transfection, filtered (0.45-m-pore-size filter; Millipore) and used to
infect 1 105 to 2 105 Jurkat T cells in complete RPMI medium supplemented
with Polybrene (4 g/ml; Sigma). Infected cell populations were selected with
puromycin (0.4 g/ml) for 7 to 10 days.
Immunoaffinity purification of Nef and associated proteins from Jurkat T
cells. Immunoaffinity purification of Nef and associated proteins was performed
as previously described (20) except for using different epitope tags. Briefly, CD4
Jurkat T cells were maintained in complete RPMI medium containing puromycin
(0.8 g/ml) in spinner cultures. Every 1 to 2 days, sufficient fresh medium was
added to adjust the cell density to 105 cells/ml. Spinner cell cultures were
expanded to 6 to 8 liters, and cells were harvested when cell densities reached 5
 105 to 7  105 cells/ml. Detergent extracts were prepared as described previ-
ously (20). Monoclonal antibody (MAb) 12CA5, specific for the HA epitope
(-H), was obtained from the Monoclonal Shared Resource at Cold Spring
Harbor Laboratory. MAb specific for AU-1 (-A) was purchased from Babco.
For immunoprecipitation experiments, -H and -A MAbs were cross-linked to
protein G-agarose beads (Roche) (17). Immunoprecipitations were performed
for 4 h, beads were washed extensively in lysis buffer, and protein complexes were
eluted in lysis buffer containing the appropriate peptide at 0.2 mg/ml. Eluates
were concentrated by using Microcon centrifugal filter devices (molecular mass
cutoff, 10 kDa; Millipore) according to the manufacturer’s instructions. Proteins
were resolved on sodium dodecyl sulfate (SDS)–8 to 17% gradient polyacryl-
amide gels and stained with silver nitrate for analytical experiments (17) or with
SimplyBlue Safe Stain (Invitrogen). Liquid chromatography-tandem mass spec-
troscopy (LC/MS/MS) microsequencing and data analysis were performed at the
Cold Spring Harbor Laboratory Cancer Center Protein Chemistry shared re-
source as described previously (20). Proteomic data were analyzed with Profound
software, which is available online from http://prowl.rockefeller.edu. Profound
uses “expectation values” to rate matches between experimental spectra and
protein sequences in the database. The simple interpretation of an expectation
value is the number of matches that would be expected to have a particular score
if the matches to the database were completely random. Therefore, the smaller
the expectation value, the more likely that a particular match is a true match
rather than a random one. The description of the Profound algorithm is available
online from http://prowl.rockefeller.edu/.
Transient assays of NMT association with Nef. Cos7 cells were transfected
with plasmid pCG expressing epitope-tagged NMT, Nef, Nef-GFP chimeras,
Gag, or Hck by electroporation, collected 36 to 48 h later, and extracted in lysis
buffer (16, 19). Extracts were immunoprecipitated with -H beads. The beads
were collected and washed two times with lysis buffer and three times with lysis
buffer supplemented with 500 mM LiCl, and samples were analyzed by immu-
noblotting.
SDS-PAGE and immunoblot analyses. T7 epitope-specific MAbs conjugated
to horseradish peroxidase and to CD3 were from Novagen and Santa Cruz
Biotechnology, respectively. Serum to recombinant SIVmac 239 Nef was raised
in rabbits (-Nef Ab; Covance) (19). Rabbit polyclonal antibody reactive with
both NMT-1 and NMT-2 (-NMT Ab) was generously provided by Benjamin
Cravatt. Polypeptides were separated by SDS–12.5% polyacrylamide gel electro-
phoresis (PAGE) and electroblotted onto polyvinylidene difluoride membranes
(Immobilon-P; Millipore). The membranes were incubated for 1 h in blocking
solution containing Tris-buffered saline (150 mM NaCl, 50 mM Tris-HCl [pH
7.5] with 0.1% Tween 20, 1% bovine serum albumin, and 5% nonfat dried milk
[Carnation]) and then incubated with appropriate antibodies in blocking solution
at the specified dilutions (-Nef, 1:1,000; -T7–horseradish peroxidase, 1:5,000;
-H, 1:5,000; -CD3, 1:1,000; -NMT, 1:400). Membranes were washed three
times with Tris-buffered saline containing 0.1% Tween 20 and, when appropriate,
were incubated for 1 h with horseradish peroxidase-conjugated goat -rabbit
immunoglobulin G antibody (Jackson Laboratories) and developed by using an
enhanced chemiluminescence (Amersham) detection system as recommended by
the manufacturer.
Glycerol gradient sedimentation. Nef and associated proteins were immuno-
precipitated from detergent extracts with -H beads, eluted with H peptide, and
overlaid onto a 5-ml, 10 to 30% glycerol gradient. Gradients were centrifuged at
45,000 rpm in an SW55 Ti rotor for 12 h at 4°C. Fractions (400 l) were collected
from the top of the gradient, and aliquots of each fraction were used for immu-
noblot analysis with -NMT Ab, -CD3, and -H MAb.
RESULTS
To facilitate the purification of Nef and its associated pro-
teins, we tagged the C-terminal end of SIVmac 239 Nef with
AU-1 (A) and HA (H) double-epitope tags (239.AH) and
expressed it stably in Jurkat T cells via retroviral transduction
and selection with puromycin. The addition of C-terminal AH
epitopes had little detectable effect on the ability of Nef to
downmodulate CD4, CD28, and CD3 from the cell surface and
to associate with p62 phosphoprotein, which was identified
previously as p21-associated kinase (PAK) (2, 36), compared
to untagged Nef. As controls we also constructed Jurkat cell
lines expressing AH epitope-tagged SIVmac 239 Nef proteins
with mutations that disrupted the N-terminal myristoylation
signal [239(G2ƒ).AH], the PxxP motif required for association
with PAK (37) [239(P104A,P107A).AH], or sequences required
for CD4 and CD28 downmodulation and located in the N-
terminal region [239(23–74).AH] (45). Finally, we constructed
a negative control cell line expressing puromycin N-acetyl-
transferase selectable marker (PAC) alone.
Detergent extracts were prepared from Jurkat T cells ex-
pressing wild-type and mutant forms of AH-tagged Nef and
from control cells transduced with a control vector expressing
PAC alone. Nef and associated proteins were purified by se-
quential immunoprecipitations with -H and then -A epitope
antibodies, followed each time by elution with the respective
peptide epitope. The immunoprecipitated proteins were sepa-
rated by SDS-PAGE and stained with silver nitrate. As shown
in Fig. 1A, two polypeptides, one with an apparent molecular
mass of approximately 65 kDa (p65) and the other with an
apparent molecular mass of 220 kDa, copurified with wild-
type and mutant SIVmac Nef proteins that contained an intact
myristoylation signal (lanes 2 to 4). Notably, these polypeptides
were absent in purifications from cells that expressed myris-
toylation signal-defective Nef [239(G2ƒ).AH] and from puro-
mycin-resistant cells that did not express 239.AH Nef (lanes 5
and 1, respectively).
To determine the identity of Nef-associated p65, 239.AH
Nef and its associated proteins were immunoprecipitated from
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approximately 1010 Jurkat T cells. The purified polypeptides
were separated on an SDS–8 to 17% gradient polyacrylamide
gel and stained with SimplyBlue Safe Stain, and a gel slice
containing p65 was excised. Proteins within the gel slice were
subjected to in-gel digestion with trypsin, and the resulting
peptides were separated and sequenced by LC/MS/MS. LC/
MS/MS data for peptides derived from p65 are listed in Table
1. Amino acid sequences of seven peptides matched those for
predicted tryptic peptides derived from human NMT-1, while
the combined expectation score (the probability that p65 is not
NMT-1) was 2.9  1028, thus indicating that Nef-associated
p65 is indeed NMT-1. To confirm that Nef-associated p65 is
NMT-1, -Nef immunoprecipitates from Jurkat cells ex-
pressing wild-type 239.AH, myristoylation signal-defective
239(G2ƒ).AH, and control puromycin-resistant Jurkat T cells
were analyzed by immunoblotting with a polyclonal antibody
that recognizes both the NMT-1 and NMT-2 isoforms of hu-
man NMT (-NMT). Two protein bands migrating at approx-
imately 65 and 60 kDa were detected in Jurkat detergent ex-
tracts (Fig. 1B, lane 1). Control experiments using ectopically
expressed NMT-1 and NMT-2 revealed that the more intense
p65 band corresponded to NMT-1, while the faster-migrating
p60 comigrated with the NMT-2 isoform (data not shown; see
Fig. 3). Notably, the p65 NMT-1, but not p60, isoform was
detected in -Nef immunoprecipitates from cells expressing
wild-type 239.AH, and this association required an intact my-
ristoylation signal in Nef (Fig. 1B, compare lanes 2 and 3). We
concluded that SIVmac 239 Nef forms a relatively abundant
and stable complex with NMT-1 in vivo.
SIV Nef was previously observed to bind cellular proteins
such as the CD3 subunit of TCR-CD3 (18). To address the
relationship between complexes containing Nef and CD3 and
those containing Nef and NMT-1, we sedimented Nef-contain-
ing complexes in a glycerol gradient. Detergent extracts were
prepared from Jurkat T cells expressing 239.AH Nef and con-
trol puromycin-resistant Jurkat cells. Nef and its associated
proteins were immunoprecipitated with -H MAb and eluted
with H peptide. Aliquots of eluates were characterized by
immunoblotting. As expected, NMT-1 and CD3 were readily
detectable in immunoprecipitates from cells expressing
239.AH but not in those from control cells (Fig. 2, left panel).
FIG. 1. Nef associates with NMT-1 in a myristoylation signal-de-
pendent manner. (A) p65 specifically copurifies with SIVmac 239 Nef.
Nef and associated proteins were isolated by use of a two-step immu-
noaffinity purification protocol from detergent extracts prepared from
Jurkat T cells expressing AH epitope-tagged wild-type (lane 2) and
mutant (lanes 3 to 5) forms of SIVmac 239 Nef. Purification from
control puromycin-resistant Jurkat cells that did not express Nef is also
shown (lane 1). Eluates were separated by SDS–8 to 17% gradient
PAGE, stained with silver nitrate, and analyzed by LC/MS/MS. Bands
corresponding to NMT-1 and SIV Nef are indicated. The bands mi-
grating just below Nef likely are Nef degradation products. The posi-
tions and molecular masses of protein standards are indicated on the
left. (B) Immunoblot analysis identifies Nef-associated p65 as N-myr-
istoyltransferase 1. Immunopurifications from Jurkat T cells expressing
wild-type (lane 3) and myristoylation signal-mutated (lane 4) SIVmac
239 Nef and from puromycin-resistant Jurkat T cells that did not
express Nef (lane 2) were resolved by SDS-PAGE and analyzed by
immunoblotting with -NMT Ab (upper panel) or -Nef Ab (bottom
panel). Extract from Jurkat cells, which express both the NMT-1 and
NMT-2 isoforms, provided a positive control for NMT expression
(lane 1). The identity of the -Nef Ab reactive band indicated with an
asterisk is not known.
TABLE 1. Nef-associated p65 is NMT-1a
Peptide Expectationvalue Peptide sequence
1 1.4  109 128LGEVVNTHGPVEPDKDNIR146
2 2.5  106 116SYQFWDTQPVPK127
3 6.3  106 345DIPVVHQLLTR355
4 1.6  105 95AIELFSVGQGPAK107
5 4.1  104 44GGLSPANDTGAK55
6 0.13 259VAPVLIR265
7 15.4 222LVGFISAIPANIHIYDTEKK241
p65 2.9  1028 N-Myristoyltransferase-1 (Homo sapiens)
a Amino acid sequences and expectation values of peptides derived from
SIVmac 239 Nef-associated p65 and analyzed by LC/MS/MS are shown. The
relative positions of peptides in the NMT-1 amino acid sequence are indicated.
The expectation value is a probability that the actual peptide data do not cor-
respond to the NMT-1 sequence. The combined expectation score for p65 shown
at the bottom is the probability that Nef-associated p65 is not NMT-1. The seven
peptides cover approximately 19% of the NMT-1 amino acid sequence.
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Next, Nef and associated proteins were sedimented through
a glycerol gradient. A set of protein standards of known mo-
lecular weights was sedimented in parallel through an identical
glycerol gradient to provide an estimate of the sizes of various
protein complexes containing Nef. The distributions of 239.AH
Nef, NMT-1, and CD3 as well as protein standards across the
gradient are shown in Fig. 2A. The approximately 35-kDa
239.AH Nef protein sedimented more slowly than the 67-kDa
standard and peaked in fractions 2 and 3. This suggested that
that the bulk of the immunoprecipitated Nef was either in
relatively low-molecular-weight complexes or uncomplexed.
Immunoblotting with -NMT Ab revealed that Nef-associated
NMT-1 sedimented more rapidly than the bulk of Nef and
peaked in fraction 4. This was consistent with the possibility
that the NMT-1 binds Nef directly and that the Nef–NMT-1
complex does not contain other components. Similarly, the
CD3 (16-kDa) subunit associated with Nef peaked in fraction
2. The small size of the Nef-CD3 complex suggested that
other TCR:CD3 subunits were absent. This was expected since
the association between CD3 and the core CD3 complex is
known to be unstable under conditions used to prepare deter-
gent extracts (45).
The Nef protein is posttranslationally modified by covalent
attachment of the myristoyl moiety to glycine 2, and this reac-
tion is catalyzed by NMT. Therefore, we hypothesized that the
Nef–NMT-1 complex could be a transient intermediate of the
myristoylation reaction of Nef. To address this possibility, we
first developed a transient-expression assay in Cos7 cells in
which to study the Nef association with NMT-1.
Cos7 cells were transfected to transiently express T7-epitope
tagged human NMT isoforms NMT-1 (T7.NMT-1) and
NMT-2 (T7.NMT-2) together with wild-type or myristoylation-
signal mutated SIVmac 239 Nef, each tagged with the AH
epitopes. Nef and associated proteins were immunoprecipi-
tated with -H MAb from detergent extracts, and the immu-
noprecipitates were separated by SDS-PAGE and analyzed by
FIG. 2. Glycerol gradient sedimentation of complexes containing SIV Nef. Detergent extracts prepared from Jurkat T cells expressing 239.AH
Nef were immunoprecipitated with a MAb specific for the H epitope (IP:-H), and bound proteins were eluted with H peptide. Nef and associated
proteins were sedimented through a 10 to 30% glycerol gradient, and fractions were collected from the top of the gradient. The distribution of
molecular mass standards sedimented in parallel in an identical gradient is indicated in panel A. (A) Aliquots of glycerol gradient fractions were
separated by SDS-PAGE and analyzed by immunoblotting with a polyclonal antibody specific for NMT (WB:-NMT), a polyclonal antibody
specific for SIVmac 239 Nef (WB:-Nef), or a MAb specific for CD3 (WB:-CD3). (B) The distributions of NMT, 239.AH Nef, and CD3 in
gradient fractions were quantitated by densitometric scanning of the chemiluminescence images shown in panel A. A representative of two
independent experiments is shown.
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immunoblotting. As shown in Fig. 3A, T7.NMT-1 migrated
more slowly than T7.NMT-2 (compare lanes 1 and 2), and the
two isoforms could easily be distinguished from each other
(lane 3). Notably, wild-type 239.AH Nef precipitated NMT-1
more efficiently than NMT-2 (lane 4), as observed previously
with Jurkat cells stably coexpressing SIVmac 239 Nef and en-
dogenous NMT. We then asked whether HIV-1 Nef also forms
a complex with NMT. We found that the HIV-1 NA7 Nef
FIG. 3. N-terminal regions of HIV-1 and SIV Nef proteins associate preferentially with the NMT-1 isoform. (A) Nef associates preferentially
with the NMT-1 isoform. Detergent extracts were prepared from Cos7 cells transiently expressing T7 epitope-tagged NMT-1 (T7.NMT-1) (lane
1), or NMT-2 (T7.NMT-2) (lane 2), or both NMT-1 and NMT-2 alone (lane 3) or together with wild-type (239.AH) (lane 4) or myristoylation-
defective [239(G2ƒ).AH] (lane 5) SIV Nef or wild-type (NA7.AH) (lane 6) or myristoylation-defective [NA7(G2A).AH] (lane 7) HIV-1 Nef. Extracts
were immunoprecipitated with -H MAb (IP:-H), and immunoprecipitates were resolved by SDS-PAGE and analyzed by Western blotting. NMT
was detected with a MAb specific for the T7 epitope (WB:-T), and Nef was detected with H epitope-specific MAb (WB:-H) in immunopre-
cipitates (upper panels) and detergent extracts (lower panels). (B) The N-terminal region of Nef preferentially binds the NMT-1 isoform.
Detergent extracts prepared from Cos7 cells transiently coexpressing T7.NMT-1 and T7.NMT-2 alone (lanes 1 and 5) or in combination with SIV
239.AH Nef (lane 2), HIV-1 NA7.AH Nef (lane 6), or chimeric molecules consisting of AH epitope-tagged GFP (GFP.AH) fused to the C-terminal
end of the full-length SIV Nef (239.GFP.AH) (lane 3), the N-terminal 30 residues of SIV Nef [239(1–30).GFP.AH] (lane 4), full-length NA7 Nef
(NA7.GFP.AH) (lane 7), the N-terminal 68 residues of NA7 Nef [NA7(1–68).GFP.AH] (lane 8), or myristoylation-defective NA7 Nef
[NA7(G2A).GFP.AH] (lane 9) were immunoprecipitated with -H MAb (IP:-H). NMT and Nef were detected in the immunoprecipitates (upper
panels), and extracts (lower panel) were resolved by SDS-PAGE.
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isolate also preferentially bound NMT-1 and that this interac-
tion required an intact Nef myristoylation signal (lanes 6 and
7), as observed for SIVmac 239 Nef.
To determine whether elements other than the myristoyl-
ation signal in Nef contribute to the interaction of Nef with
NMT-1, we constructed chimeric proteins comprised of the
amino-terminal regions of SIV and HIV-1 Nef fused to GFP.
To facilitate immunoprecipitation experiments, we tagged
GFP with the AH epitopes (GFP.AH). We tested the chimeric
proteins for their ability to associate with NMT-1 and NMT-2
in Cos7 cells. As shown in Fig. 3B, a short N-terminal fragment
of 239 Nef consisting of only the first 30 amino acid residues
was sufficient to preferentially bind NMT-1 over NMT-2 (lane
4). Similarly, the (N-terminal) first 68 amino acids of HIV-1
NA7 Nef was also sufficient to preferentially precipitate
NMT-1 (lane 8). Notably, both of these Nef fragments precip-
itated NMT less efficiently than the full-length proteins (com-
pare lanes 3 and 4 and lanes 7 and 8), which suggested that
additional elements in Nef contribute to the interaction with
NMT.
The catalytic cycle of NMT is thought to involve binding of
myristoyl-CoA by NMT, which then opens the NMT substrate
binding site and permits substrate binding. This is followed by
the transfer of the myristoyl moiety onto glycine 2 in the
substrate and the subsequent release of the myristoylated
product (7). The release of the product is thought to be the
step that limits the reaction rate (11). Therefore, we reasoned
that if the Nef-NMT complex is indeed a transient intermedi-
ate of Nef myristoylation by NMT-1, it may be possible to
modulate its abundance by altering the size of the myristoyl-
CoA pool in the cell. To test this possibility, we attempted to
alter the intracellular pool of myristoyl-CoA by using pharma-
cologic approaches, and we then measured the effects on the
abundance of Nef-NMT complexes.
First, we attempted to increase the myristoyl-CoA pool in
Cos7 cells transiently coexpressing NMT-1, NMT-2, and NA7
Nef. Since previous studies demonstrated that the availability
of fatty acids is limiting to the synthesis of their respective
acyl-CoA by fatty acyl-CoA synthetase (48, 49), we cultured
cells in the presence of exogenous myristic acid (C14:0). Sec-
ond, we attempted to decrease the intracellular pool of all fatty
acyl-CoA species by treating the cells with an inhibitor of fatty
acyl-CoA synthetase, Triacsin C (47). As controls, cells were
cultured in the absence of any treatment or in the presence of
lauric acid (C12:0) or palmitic acid (C16:0), which do not affect
the myristoyl-CoA pool. Following the treatments, Nef was
immunoprecipitated from detergent extracts and Nef-associ-
ated NMT and Nef were detected by immunoblotting.
Culture of cells in the presence of myristic acid resulted in
approximately a two- to threefold decrease in the amount of
Nef-bound NMT-1 compared to that in the control cells (Fig.
4A, compare lanes 2 and 4, see also Fig. 4B). In contrast,
treatment of cells with Triacsin C resulted in the two- to three-
fold increase in the amount of Nef-bound NMT-1 (compare
lanes 2 and 7). As expected, neither lauric acid nor palmitic
acid had a detectable effect on the Nef-NMT association (com-
pare lanes 2, 3, and 5). Notably, none of these treatments
affected the overall expression levels of Nef and NMT-1. Thus,
the abundance of Nef–NMT-1 complex was inversely corre-
lated to the size of the myristoyl-CoA pool in the cells.
Together, our observations suggested that formation of the
NMT-Nef complex is a consequence of the mechanism of the
myristoylation reaction. If so, the existence of such enzyme-
substrate complexes would not be limited to NMT-1 and Nef
but should be seen also with other viral and cellular protein
substrates. To address this possibility, two additional NMT
substrates, protein tyrosine kinase Hck and HIV-1 Gag, were
FIG. 4. Agents that alter the myristoyl-CoA pool modulate the
Nef-NMT-1 complex. (A) Cos7 cells coexpressing T7.NMT-1 and
T7.NMT-2, either alone (lanes 1 and 6), or together with wild-type (wt)
(NA7.AH) (lanes 2 to 5 and 7) or myristoylation-defective
[NA7(G2A).H] (lane 8) HIV-1 Nef were cultured in the presence of 50
mM lauric acid (lane 3), 50 mM myristic acid (lane 4), 50 mM palmitic
acid (lane 5), or 5 M Triacsin C (lanes 6 to 8) or left untreated (lane
1). Nef-associated NMT was immunoprecipitated from detergent ex-
tracts with -H MAb (IP:-H). Immunoprecipitates and aliquots of
detergent extracts were resolved by SDS-PAGE, and NMT-1 and
NMT-2 were detected by immunoblotting with T7 epitope-specific
MAb (WB:-T), whereas Nef was detected with H epitope-specific
MAb (WB:-H). (B) Nef-associated NMT-1 and NMT-2 were quan-
titated by densitometry scanning of chemiluminescence images such as
those shown in panel A. Mean values and standard deviations from
three independent experiments are shown. Data were normalized to
the NMT-1 associated with the NA7.AH Nef in untreated cells (lane
2).
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tested. H epitope-tagged Gag and Hck were coexpressed with
NMT isoforms in Cos-7 cells, detergent extracts were immu-
noprecipitated with -H, beads and NMT isoforms were de-
tected by immunoblotting. As shown in Fig. 5, NMT was
readily detected in both HIV-1 Gag and Hck immunoprecipi-
tates (lanes 3 and 4). Notably, Gag precipitated predominantly
NMT-2, while Hck bound more NMT-1 isoform. We con-
cluded that human NMTs form stable intermediate complexes
with their protein substrates.
DISCUSSION
Nef proteins interact with a large number of downstream
effectors. These include components of the signal transduction
machinery such as protein tyrosine and protein serine kinases,
guanine nucleotide exchange factors, cell surface receptors,
and components of the endocytic and protein-sorting machin-
eries, including clathrin adaptor complexes and other proteins
that mediate the traffic between various membrane compart-
ments (2, 6, 10, 16, 20, 23, 25, 31, 37, 40). A subset of these
proteins, such as CD3 and p62 phosphoprotein (data not
shown), were readily detectable in the -Nef immune com-
plexes that we isolated, while others were not. We were unable
to detect several of the previously implicated Nef partners
despite using numbers of cells that greatly exceeded those used
in the previous experiments and employing sensitive immuno-
blot as well as LC/MS/MS analyses. Specifically, we did not
observe Nef associations with subunits of clathrin adaptor
complexes, Lck, Fyn, and Vav. The inability to detect these
proteins could be due to several factors, including the possi-
bility that these associations were transient or unstable under
our experimental conditions or were poorly conserved in the
nef alleles that we employed.
The spectrum of proteins that were shown here to copurify
with AU-1–HA epitope-tagged SIV Nef (239.AH) differed
from that previously reported by us for HA-FLAG epitope-
tagged HIV-1 Nef (NA7.hf) (20). Nevertheless, several lines of
evidence indicate that HIV-1 NA7 and SIVmac 239 Nef pro-
teins target very similar spectra of cellular proteins and that the
use of the hf epitope tag (20) results in a better recovery of
Nef-associated protein complexes (A. Janardhan, B. Hill, and
J. Skowronski, unpublished data). This is supported by the
results of recent experiments in which SIVmac 239 Nef tagged
with the hf epitope (239.hf) was expressed in Jurkat T cells and
239.hf Nef-associated polypeptides were purified by using an
immunoaffinity strategy described by us previously (20). Mi-
croseqencing revealed that 239.hf Nef binds a spectrum of
polypeptides that is very similar to that bound by hf-tagged
HIV-1 Nef (20), including DOCK2, ELMO1, Rac, and NMT-1
(data not shown). Moreover, microsequencing of HIV-1
NA7.hf Nef-associated proteins (20) resulted in identification
of seven NMT-1-derived peptides with a combined expectation
score for NMT-1 of approximately 5 1014 (data not shown),
thus indicating that NMT-1 binds Nef regardless of the specific
epitope tag used. How could the use of different epitope tags
at the C terminus of Nef affect the recovery of Nef-associated
proteins? The AH-epitope tag is approximately 10 amino acid
residues shorter than the hf tag. Thus, the AH tag is more
likely to be buried in Nef-bound protein complexes, while the
hf tag is more likely to be accessible to antibodies used for
immunopurification. Therefore, it is not surprising that in the
context of NMT-1, which binds the very N-terminal surface in
the Nef molecule, both the AH and hf C-terminal tags were
accessible and permitted efficient immunopurification of the
Nef–NMT-1 complexes. In contrast, in the context of the
DOCK2-ELMO1-Rac complex, which binds a surface located
more centrally in the Nef molecule (20), only the longer hf
epitope tag was available for immunopurification. Thus, it is
important to use an optimal epitope tagging strategy that will
not interfere with protein function and that will address po-
tential limitations to protein immunopurification imposed by
the topology of protein complexes.
We purified and characterized a novel protein complex con-
taining lentiviral Nef and N-myristoyltransferase-1. Our data
showed that the association of Nef with NMT requires an
intact myristoylation signal at the N terminus of Nef and that
a short N-terminal region of Nef is sufficient for binding. Nev-
ertheless, sequence elements located downstream in Nef likely
contribute to the interaction, since the association of the full-
length Nef proteins with NMT was more robust than that of
chimeras containing only their N-terminal regions. The fact
that the intact myristoylation signal in Nef was required for
NMT binding suggested that the Nef–NMT-1 complex we pu-
rified is an intermediate of Nef myristoylation. This possibility
is further supported by the observation that the abundance of
FIG. 5. HIV-1 Gag and Hck form stable complexes with NMT
isoforms. Detergent extracts prepared from Cos7 cells transiently co-
expressing T7 epitope-tagged NMT-1 and NMT-2 alone (lane 1) or
together with H epitope-tagged HIV-1 Gag (Gag.H) (lane 3), Hck
(Hck.H) (lane 4), or, as controls, wild-type NA7 (NA7.AH) (lane 2) or
myristoylation-defective [NA7(G2A).AH] (lane 5) HIV-1 Nef were im-
munoprecipitated with -H MAb (IP:-H), and immunoprecipitates
were resolved by SDS-PAGE and analyzed by Western blotting as
described in the legend to Fig. 3.
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the Nef–NMT-1 complex is modulated by altering the myris-
toyl-CoA pool in the cell and that NMT isoforms also form
stable complexes with other substrates. The current model of
the NMT catalytic cycle is based on extensive in vitro studies of
yeast (Saccharomyces cerevisiae) N-myristoyltransferase (7).
This model predicts that an increase in the intracellular myr-
istoyl-CoA pool will facilitate substrate loading and therefore
should lead to an increase in the steady-state level of a sub-
strate-NMT complex. Conversely, a decrease in the intracellu-
lar myristoyl-CoA pool is predicted to have the opposite effect.
Surprisingly, and contrary to these predictions, we observed
that the abundance of the Nef–NMT-1 complex is inversely
correlated with the size of the myristoyl-CoA pool. One pos-
sible explanation for this inconsistency is that the release of the
myristoylated product from NMT is coupled to myristoyl-CoA
loading onto the product-enzyme complex. This possibility is
attractive because dissociation of the product-enzyme complex
is thought to be the rate-limiting step of the myristoylation
reaction (11). Alternatively, our observations may reflect dif-
ferences between mechanisms of catalysis by the mammalian
and yeast enzymes or levels of regulation in vivo that were not
appreciated from in vitro experimentation.
Amino acid sequences of NMT-1 and NMT-2 share approx-
imately 80% amino acid sequence identity. Notably, most di-
vergent are the N-terminal regions, and the differences are
strictly conserved among mammals. This suggests unique yet
presently unknown roles for each enzyme in vivo, even though
previous studies using a spectrum of peptide substrates re-
vealed that NMT-1 and NMT-2 show similar substrate prefer-
ences in vitro (12). Therefore, it is intriguing that HIV-1 Gag
detectably bound only NMT-2, while Nef displayed high pref-
erence towards NMT-1. The specific recognition of different
NMT isoforms by Gag and Nef suggests that each of these two
viral substrates may be myristoylated preferentially by a dis-
tinct NMT isoform in vivo. Further studies of the interactions
of NMT-1 and NMT-2 isoforms with Nef and other viral and
cellular protein substrates will likely reveal previously unap-
preciated levels of regulation of protein myristoylation. The
differential recognition of NMT isoforms by viral and cellular
substrates reported here suggests that development of selective
NMT inhibitors that target myristoylation of specific viral sub-
strates may be possible.
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